Acadia Sues to Block Copies of Nuplazid, Its Only Drug

Acadia said generic versions of Nuplazid capsules and tablets proposed by Teva and four other companies infringe as many as five patents for the drug, used to treat hallucinations and delusions associated with Parkinson’s disease.

• Acadia is seeking court orders blocking copies until the patents have expired, and to collect cash compensation if copies are made before then, according to complaints filed Thursday and July 24 in federal court in Wilmington, Delaware
• Acadia accused Teva and Aurobindo of infringing four patents, Hetero of infringing three, MSN two and Zydus Cadila all five, according to complaints
• Nuplazid had sales of $90.1 ...